Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12801798 | 1.00 | P2RX7 (0.45) | P2RX7CYP19A1 | |
| SCHEMBL1670637 | 1.00 | P2RX7 (0.45) | P2RX7CYP19A1 | |
| SCHEMBL828687 | 0.85 | CYP19A1 (0.38) | P2RX7CYP19A1 | |
| SCHEMBL12801795 | 0.83 | P2RX7 (0.41) | P2RX7 | |
| SCHEMBL829272 | 0.78 | HTR1A (0.35) | P2RX7CYP19A1 | |
| SCHEMBL31463313 | 0.78 | HTR1A (0.35) | P2RX7CYP19A1 | |
| SCHEMBL830235 | 0.78 | HTR1A (0.35) | P2RX7CYP19A1 | |
| SCHEMBL15674592 | 0.78 | HTR1A (0.35) | P2RX7CYP19A1 | |
| SCHEMBL15674591 | 0.78 | HTR1A (0.35) | P2RX7CYP19A1 | |
| SCHEMBL828719 | 0.75 | ACHE (0.36) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119955757-A | Solvent-tolerant transaminase mutant, genetically engineered bacterium and application of transaminase mutant and genetically engineered bacterium in preparation of retipam intermediate | 浙江工业大学 | 2025-05-09 | — | — | CN | claimed |
| CN-119955757-A | Solvent-tolerant transaminase mutant, genetically engineered bacterium and application of transaminase mutant and genetically engineered bacterium in preparation of retipam intermediate | 浙江工业大学 | 2025-05-09 | — | — | CN | disclosed |
| CN-117802178-A | Method for preparing zimetapam by chemical-enzymatic method | 尚科生物医药（上海）有限公司 | 2024-04-02 | — | — | CN | disclosed |